Submitting Review Outcomes and Creating a Continuing Authorisation Request

If a patient requires a Continuing Treatment, a Review or to Cease Treatment for Immunoglobulin (Ig), a **Review Outcomes Form** will need to be submitted through a **Record Review.**

The form can be found through the following methods:

1. Home page under **Pending Reviews** tab
2. **Patient Record** page under **Current Authorisation**
3. **View Authorisation** page under **Record Review** tab
4. **BloodSTAR Messages** page under **Review Reminder**

How to Navigate to the Review Outcome Form – Record Review

Option 1:
From the Home page, select the **Pending Review** tab. Select **Record Review** on the patient that requires the review.



Option 2:
From the **Patient Record** page, scroll down to **Current Authorisation** and select **Record Review** on the bottom right-hand corner.



Option 3:
From the **View Authorisation** page, select the **Record Review** tab. Select **+ Record Review** button.



Option 4:
Once an approved Immunoglobulin (Ig) Authorisation is nearing or has just exceeded its expiry date, BloodSTAR will notify Medical Officers involved with the authorisation and prompt them to submit review outcomes and will provide the option to submit a Record Review Outcomes.



Before requesting for a continuing authorisation request, check there are no more remaining doses on the current treatment plan. If there are planned doses remaining, they will be deleted after a new continuing authorisation request is submitted.

Note: A request for continuing supply is conditional on a review being conducted within 8 weeks of the **Authorisation End Date** with specified date displayed in brackets.

Remaining doses can be checked through the following 3 options:

Check remaining doses for a patient's authorisation

Option 1:
From the **Patient Record** page, scroll down to **Current Authorisation** under **Final Dose Planned Date.** This will also be displayed on the **View Authorisation** page.

This section will display either:

- A date which is based on the *planned date* or *partially dispensed,* or
- *No remaining dose* text will display if there are no remaining planned doses.



Option 2:
From the **Patient Record** page, scroll down to **Current Authorisation** select **Treatment Plan** hyperlink. The **Treatment Plan** will pop-up. Scroll down to the bottom where the final planned date will be displayed.





Option 3:
From the **View Authorisation** page, scroll down to the bottom of the **Treatment Plan** where the final planned date will be displayed.

Treatment Plan

This treatment plan does not constitute a prescription for immunoglobulin products.

Planned Date	Dose Type	Dose	Status	Requested	Expected Infusion Date	Date Dispensed	Dispensed
06-Nov-2024	Maintenance Dose (SCIg)	Hizentra 20% - 40.00 g in 8 divisions	Planned	✔	06-Nov-2024		
01-Jan-2025	Maintenance Dose (SCIg)	Hizentra 20% - 40.00 g in 8 divisions	Planned				
26-Feb-2025	Maintenance Dose (SCIg)	Hizentra 20% - 40.00 g in 8 divisions	Planned				
23-Apr-2025	Maintenance Dose (SCIg)	Hizentra 20% - 40.00 g in 8 divisions	Planned				

Submitting a Review Outcome Form – Requesting Continuing Treatment

1. On the **Review Outcome Form,** fill in the Review Details, Review Criteria and select **Request Continuing Treatment** in the Review Outcome.



Review Details

Review Date * 11-Nov-2024

Reviewing Medical Officer * I am the Reviewing Medical Officer
Select existing Treating Medical Specialist
Nominate a Reviewing Medical Officer
The Criteria requires that a review must be undertaken by a specialist.

Review Criteria

Select all review criteria that the patient's condition meets

Initial review is required within six months and ongoing reviews by a specialist at least annually to assess clinical benefit. Documentation of clinical effectiveness is necessary for continuation of Ig therapy. Read more

☐ Monitoring of trough or serum immunoglobulin levels (IgG, IgA and IgM) and any history of infection

AND

☐ There should be regular consideration of a trial period of cessation of Ig for the purposes of immunological evaluation unless medically contraindicated on safety grounds (for example active bronchiectasis and/or suppurative lung disease, neutropenia, or ongoing immunosuppressant medication) or where there is persistence of the underlying condition that would result in severe hypogammaglobulinaemia in the absence of Ig replacement therapy. Trial cessation is best commenced in September or October.

When IgA and IgM are trending upwards and close to normal and the patient is well, a trial off therapy (in September or October) is considered to allow immunological re-evaluation, or is medically contraindicated.

Please note: A diagnosis of bronchiectasis and/or suppurative lung disease must be consistent the guideline of the Thoracic Society of Australia and New Zealand (Chang AB et al. 2014).

Review Outcome

Review Outcome *

○ **Request Continuing Treatment**
These review outcomes provide supporting information for the assessment of an additional authorisation period.

○ **Review Only**
Record a review without requesting continuing treatment. Access to therapy will continue unchanged to the authorisation end date.

○ **Cease Treatment**
End the current authorisation because Ig therapy is no longer required, or is being requested under a different indication.

Note: When requesting continuing treatment, if no doses have been dispensed on the patient's current authorisation, a blue notification will be displayed, and the option can't be selected. The message is as follows.



2. The page will update, displaying the Continuing Authorisation Request.

Note: If there are planned doses remaining in the current treatment plan, it will be deleted and the Date Required can't be selected before this date. A warning message will be displayed, and the message is as follows



3. Fill in all the relevant fields below.

Note: BloodSTAR will display the patients **Last Recorded Weight** if there was a previous authorisation request



Note: The system will prepopulate the **Date Required** to be the same as the next planned date and display a message saying Date required matches the next planned date. There is no treatment gap.



Note: If the date required is changed, creating a *treatment gap, t*he system will display a pop-up message advising the date entered creates a treatment gap and will suggest an alternative treatment date to avoid a gap in treatment. The suggested date is based on the frequency selected in the new request.



There are two ways of recording patient review outcomes.
Option A: If you select **No – keep the date entered**, the date you entered (e.g. 20 May 2023) will become the date of the first approved dose for this Continuing Authorisation Request. This may cause a gap in the treatment as specified in the pop-up.

Option B: If you select **Yes – change date to [Insert date],** the date suggested by the system (e.g. 28 April 2023, in the example above) will be the date of the first dose for this Continuing Authorisation Request. This function is designed to reduce the number of unintentional gaps in a patient's treatment plan.

4. Once complete, confirm contact details and tick the box to indicate all information submitted is accurate and true. Select **Submit**.



5. A notification will acknowledge the request has been submitted for Lifeblood Authorisers to review, and the outcome will be displayed in BloodSTAR Messages.


Request Submitted
Your request has been submitted for assessment. You will be advised of the outcome of the assessment via BloodSTAR Messages.
Request Date:
Patient:
Requesting Medical Officer:
Urgency:
Reference Number:

Medical Officers can review a patient's authorisation without requesting for continuing treatment.

Review Outcome Form – Review Only

1. On the **Review Outcome Form,** fill in the Review Details, Review Criteria and select **Review Only** in the Review Outcome.



2. Once complete, select **Submit**.



3. A notification will acknowledge the request has been submitted and navigate back to the **Patient Record** page.


Your review outcomes have been saved.

Medical Officers can cease a patient's current authorisation if it is no longer required or is being requested under a different indication. You have the option to cease treatment immediately or to choose a later date.

Review Outcome Form – Cease Treatment

1. On the **Review Outcome Form,** fill in the Review Details, Review Criteria and select **Cease Treatment** in the Review Outcome.



2. Select an option in the **Cessation Date.**

	Note: If there are planned doses remaining in the patient's authorisation, ceasing treatment will cancel all the planned doses after the selected cessation date. A warning message will be displayed, and the message is as follows.



4. A notification will acknowledge the request has been submitted and navigate back to the **Patient Record** page



5. To view the ceased Authorisation, select **Record Review** under **View Authorisation.**